PRKCI and prostate cancer: In addition to the effects on cardiomyogenesis, PKCι inhibition has been proposed as a novel therapeutic target for acute pain syndrome [24], inflammatory disorders [25], and various cancers including prostate cancer [26], neuroblastoma [23], glioblastoma [27,28], pancreatic cancer [29], and melanoma [30].